Medical Device News Magazine

Inspira Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients – Potentially Targets $2.5 Billion ABG Market

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a groundbreaking respiratory support technology company, revealed the development of the HYLA™ blood sensor.

Without the need to take actual blood samples from patients, Inspira’s non-invasive optical blood sensor is being designed to perform real-time and continuous blood monitoring to alert physicians of immediate signs of changes in a patient’s clinical condition. The HYLA blood sensor is targeting the potential $2.5 billion Point of Care testing, ABG (Arterial Blood Gas) analyzer market.

The non-invasive HYLA blood sensor is being developed by a team of cyber-warfare specialists who formerly served in the Israeli Defense Forces’ elite cyber-attack special forces. The HYLA blood sensor is being designed as a new platform based on key technologies being developed for Inspira’s ART™ system, designed to reduce the need for invasive mechanical ventilation. Like the ART system, the HYLA blood sensor is designed to minimize the need for invasive medical procedures with the intention of reducing risks, complications and costs.

Expanding Market Growth Opportunities

The HYLA™ non-invasive blood sensor is attached to the outer walls of a tube that has blood flowing through it. The HYLA blood sensor may have broad application potential, benefiting patients undergoing procedures including intensive care unit (ICU) monitoring (approximately 40% of patients have a standard arterial line), Invasive Mechanical Ventilation, Extracorporeal Membrane Oxygenation (ECMO), Dialysis and Cardiopulmonary bypass. Targeted patient populations can potentially include those suffering from acute respiratory failure, cardiac failure, pneumonia, acute kidney injury (AKI), as well as patients undergoing open-heart surgery.

Real-time patient monitoring can potentially save lives

Currently, in order to identify changes in a patient’s medical condition, frequent invasive blood tests are needed. As a non-invasive real-time blood sensor, the HYLA is expected to reduce the need for frequent invasive blood tests.

The HYLA blood sensor is expected to continuously measure several key indicators such as the levels of partial oxygen and carbon dioxide pressures, known to be precise indicators of health disorders and patient deterioration.

Dagi Ben-Noon, Inspira Technologies’ Chief Executive Officer, stated: “Inspira Technologies has set out to change the way we monitor patient health. Today, hospital patients are reliant on physicians manually monitoring their health condition with invasive blood tests, as much as several times a day.”

He concluded, “We believe that the HYLA blood sensor has the potential to change patient experience and outcomes, through the non-invasive blood sensor, that is intended to perform real-time and continuous blood monitoring, with the intention of alerting physicians of changes in a patient’s clinical condition that could potentially save lives.”

This technology has not been tested or used in humans and is subject to regulatory approval.


Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”